Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis

AIDS. 2022 Nov 1;36(13):1897-1898. doi: 10.1097/QAD.0000000000003322.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents* / therapeutic use
  • Diketopiperazines
  • Drug Resistance
  • HIV Infections* / drug therapy
  • HIV Infections* / prevention & control
  • Heterocyclic Compounds, 3-Ring
  • Humans
  • Oxazines
  • Piperazines
  • Pre-Exposure Prophylaxis*
  • Pyridones / therapeutic use
  • Rilpivirine / therapeutic use

Substances

  • Anti-HIV Agents
  • Diketopiperazines
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • dolutegravir
  • Rilpivirine
  • cabotegravir